Alessandro Laghi
Research Subjects
Alessandro Laghi has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Donato Di Nunno
Department of Medicine, Dermatology and STDs Unit “Celio” Military Hospital Rome Italy
2 shared publications - Giorgio Troiani
Department of Medicine, Dermatology and STDs Unit “Celio” Military Hospital Rome Italy
2 shared publications - Marco Ardigò
Dermatology Unit, IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy
2 shared publications - Stefano Astorino
Division of Dermatology, Celio Hospital, Rome, Italy
2 shared publications Antonia Marina La Malfa
Hospital Pharmacy Regina Elena National Cancer Institute – IRCCS Rome Italy
1 shared publication- Camilla Chello
Dermatology Clinic, Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Rome, Italy
1 shared publication
Latest Publications
- 26 February 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (4)
Minimising Late Scar Widening of the Dorsal Trunk in Young Adults: A Prospective Study of the Dermo‐Epidermally Anchored Trapezoidal Excision (DATE) Technique
Introduction: Late scar widening is a common but underrecognized complication of dorsal fusiform excisions, especially in young adults with high dermal elasticity and physically active lifestyles. Objective: To evaluate the effectiveness of Dermo‐epidermally Anchored Trapezoidal Excision (DATE), a technique designed to minimise long‐term scar diastasis. Methods: This prospective, two‐arm, open‐label study was conducted between January 2015 and February 2022 at the “Celio” Military Hospital, Rome, Italy. Healthy adults aged 18–31 years undergoing elective dorsal trunk excisions were allocated by surgical scheduling to either standard fusiform excision (control) or the DATE technique (experimental). Scar widening was evaluated at 12 months using the Scar Diastasis Index (SDI). Results: A total of 273 patients were enrolled (126 control, 147 experimental), with comparable baseline characteristics. At 12 months, the DATE arm showed a significantly lower mean SDI (22.10 ± 7.05) compared to the control group (63.35 ± 11.52; p < 0.001). Patients in the experimental group experienced temporary swelling along the scar line or small stitch marks, but these resolved within a few weeks. Conclusions: DATE is a safe, reproducible, and cost‐effective technique. In young adults with high aesthetic expectations, it led to significantly narrower scars than the standard fusiform approach and may represent the preferred option for dorsal excisions.
- 26 February 2026
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 67 (4)
Minimising Late Scar Widening of the Dorsal Trunk in Young Adults: A Prospective Study of the Dermo‐Epidermally Anchored Trapezoidal Excision (DATE) Technique
Introduction: Late scar widening is a common but underrecognized complication of dorsal fusiform excisions, especially in young adults with high dermal elasticity and physically active lifestyles. Objective: To evaluate the effectiveness of Dermo‐epidermally Anchored Trapezoidal Excision (DATE), a technique designed to minimise long‐term scar diastasis. Methods: This prospective, two‐arm, open‐label study was conducted between January 2015 and February 2022 at the “Celio” Military Hospital, Rome, Italy. Healthy adults aged 18–31 years undergoing elective dorsal trunk excisions were allocated by surgical scheduling to either standard fusiform excision (control) or the DATE technique (experimental). Scar widening was evaluated at 12 months using the Scar Diastasis Index (SDI). Results: A total of 273 patients were enrolled (126 control, 147 experimental), with comparable baseline characteristics. At 12 months, the DATE arm showed a significantly lower mean SDI (22.10 ± 7.05) compared to the control group (63.35 ± 11.52; p < 0.001). Patients in the experimental group experienced temporary swelling along the scar line or small stitch marks, but these resolved within a few weeks. Conclusions: DATE is a safe, reproducible, and cost‐effective technique. In young adults with high aesthetic expectations, it led to significantly narrower scars than the standard fusiform approach and may represent the preferred option for dorsal excisions.
- Open Access
- 31 October 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (4) , 5260
Non-Invasive Skin Imaging of Pseudoxanthoma Elasticum Using Dynamic Optical Coherence Tomography: Insights from a Case-Control Study
Introduction: Pseudoxanthoma elasticum (PXE) is a rare genetic disorder characterized by progressive mineralization and fragmentation of elastic fibers, leading to multisystem involvement. Diagnosis relies on clinical features, histopathology, and, in selected cases, genetic testing, with cutaneous manifestations often representing the earliest signs. Objective: To validate dynamic optical coherence tomography (D-OCT) as a noninvasive diagnostic method for detecting PXE-related dermal abnormalities. Methods: In this case-control study, PXE patients evaluated at Umberto I Policlinic (Rome, Italy) between May 2023 and September 2024 underwent clinical and instrumental assessment. The left lateral cervical, retrocervical, left axillary, and periumbilical folds were analyzed using a standardized 0–3 clinical severity scale and D-OCT imaging. Control subjects were individuals undergoing routine mole checks. D-OCT quantified fiber density, attenuation, and vessel density at 300 µm and 500 µm depths. Statistical analysis included Spearman’s correlation and the Mann-Whitney U test, with p < 0.05 considered significant. Results: Twenty-three PXE patients and eleven controls were included. Cutaneous involvement was observed in 91.30% of patients, predominantly in retrocervical (86.95%) and lateral cervical (82.60%) areas. Clinical severity significantly correlated with D-OCT fiber density in the retrocervical region (ρ = 0.507). Compared with controls, PXE patients showed reduced fiber density and increased attenuation across most regions, except the axillae. At 500 µm depth, vessel density was markedly decreased in the axillary area, with approximately 2.5-fold fewer vessels in PXE skin. Conclusion: D-OCT effectively detects dermal alterations in PXE, including subclinical changes, providing a promising noninvasive alternative to skin biopsy.
- 31 October 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (4) , 5260
Open AccessNon-Invasive Skin Imaging of Pseudoxanthoma Elasticum Using Dynamic Optical Coherence Tomography: Insights from a Case-Control Study
Introduction: Pseudoxanthoma elasticum (PXE) is a rare genetic disorder characterized by progressive mineralization and fragmentation of elastic fibers, leading to multisystem involvement. Diagnosis relies on clinical features, histopathology, and, in selected cases, genetic testing, with cutaneous manifestations often representing the earliest signs. Objective: To validate dynamic optical coherence tomography (D-OCT) as a noninvasive diagnostic method for detecting PXE-related dermal abnormalities. Methods: In this case-control study, PXE patients evaluated at Umberto I Policlinic (Rome, Italy) between May 2023 and September 2024 underwent clinical and instrumental assessment. The left lateral cervical, retrocervical, left axillary, and periumbilical folds were analyzed using a standardized 0–3 clinical severity scale and D-OCT imaging. Control subjects were individuals undergoing routine mole checks. D-OCT quantified fiber density, attenuation, and vessel density at 300 µm and 500 µm depths. Statistical analysis included Spearman’s correlation and the Mann-Whitney U test, with p < 0.05 considered significant. Results: Twenty-three PXE patients and eleven controls were included. Cutaneous involvement was observed in 91.30% of patients, predominantly in retrocervical (86.95%) and lateral cervical (82.60%) areas. Clinical severity significantly correlated with D-OCT fiber density in the retrocervical region (ρ = 0.507). Compared with controls, PXE patients showed reduced fiber density and increased attenuation across most regions, except the axillae. At 500 µm depth, vessel density was markedly decreased in the axillary area, with approximately 2.5-fold fewer vessels in PXE skin. Conclusion: D-OCT effectively detects dermal alterations in PXE, including subclinical changes, providing a promising noninvasive alternative to skin biopsy.
- 8 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , E231-E232
Scar diastasis index: a smart and reproducible tool to evaluate long‐standing scars
- 8 October 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (2) , E231-E232
Scar diastasis index: a smart and reproducible tool to evaluate long‐standing scars
- 27 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15683
Topical chlormethine gel in the treatment of mycosis fungoides: A single‐center real‐life experience and systematic review of the literature
Gel formulation of chlormethine (CG) has gained a preeminent role among therapies available for mycosis fungoides (MF). To evaluate the frequency of use of CG for MF treatment and to determine the limits and potentialities of CG in a real-world setting. A systematic review of articles published prior to October 2021 was performed. Articles were included in the review if a full-text English version was available. MEDLINE (PubMed), Scopus, and Web of Science were each queried from their date of inception with the following terms: "mechlorethamine gel", "chlormethine gel", and "mycosis fungoides". The reference lists of the studies retrieved were searched manually. Moreover, this study included all consecutive patients with different stages of MF (from IA to IIB) who started treatment with CG gel between July 2020 and May 2021. Data of the literature were compared to our single-center real-life experience. Of the surveyed literature, 11 publications were included in the final analysis describing a total of 548 patients with MF. Eleven patients with a median (standard deviation) age of 66 years (15.1) were enrolled and followed up, receiving CG (0.02% chlormethine HCl). Response to treatment resulted higher (90.1%) in our study population than in other real-world experiences published in literature. This systematic review supports the role of CG for MF treatment, showing its limits and potentialities. Our single-center real-life experience revealed an elevated percentage of clinical response with high safety and tolerance, demonstrating its versatile use with dose and application rate adaptability.
- 27 July 2022
- Published by Wiley in Dermatologic Therapy
- Vol. 35 (9) , e15683
Topical chlormethine gel in the treatment of mycosis fungoides: A single‐center real‐life experience and systematic review of the literature
Gel formulation of chlormethine (CG) has gained a preeminent role among therapies available for mycosis fungoides (MF). To evaluate the frequency of use of CG for MF treatment and to determine the limits and potentialities of CG in a real-world setting. A systematic review of articles published prior to October 2021 was performed. Articles were included in the review if a full-text English version was available. MEDLINE (PubMed), Scopus, and Web of Science were each queried from their date of inception with the following terms: "mechlorethamine gel", "chlormethine gel", and "mycosis fungoides". The reference lists of the studies retrieved were searched manually. Moreover, this study included all consecutive patients with different stages of MF (from IA to IIB) who started treatment with CG gel between July 2020 and May 2021. Data of the literature were compared to our single-center real-life experience. Of the surveyed literature, 11 publications were included in the final analysis describing a total of 548 patients with MF. Eleven patients with a median (standard deviation) age of 66 years (15.1) were enrolled and followed up, receiving CG (0.02% chlormethine HCl). Response to treatment resulted higher (90.1%) in our study population than in other real-world experiences published in literature. This systematic review supports the role of CG for MF treatment, showing its limits and potentialities. Our single-center real-life experience revealed an elevated percentage of clinical response with high safety and tolerance, demonstrating its versatile use with dose and application rate adaptability.